HRP20160577T4 - Liječenje osteoartritisa - Google Patents

Liječenje osteoartritisa Download PDF

Info

Publication number
HRP20160577T4
HRP20160577T4 HRP20160577TT HRP20160577T HRP20160577T4 HR P20160577 T4 HRP20160577 T4 HR P20160577T4 HR P20160577T T HRP20160577T T HR P20160577TT HR P20160577 T HRP20160577 T HR P20160577T HR P20160577 T4 HRP20160577 T4 HR P20160577T4
Authority
HR
Croatia
Prior art keywords
antibody
intended
seq
amino acid
acid sequence
Prior art date
Application number
HRP20160577TT
Other languages
English (en)
Croatian (hr)
Inventor
John Allan Hamilton
Andrew David Cook
Original Assignee
The University Of Melbourne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42286786&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20160577(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The University Of Melbourne filed Critical The University Of Melbourne
Publication of HRP20160577T1 publication Critical patent/HRP20160577T1/hr
Publication of HRP20160577T4 publication Critical patent/HRP20160577T4/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Virology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Polarising Elements (AREA)
  • Glass Compositions (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
HRP20160577TT 2008-12-22 2009-12-21 Liječenje osteoartritisa HRP20160577T4 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13967908P 2008-12-22 2008-12-22
US16448609P 2009-03-30 2009-03-30
EP09833924.5A EP2376121B2 (en) 2008-12-22 2009-12-21 Osteoarthritis treatment
PCT/AU2009/001672 WO2010071924A1 (en) 2008-12-22 2009-12-21 Osteoarthritis treatment

Publications (2)

Publication Number Publication Date
HRP20160577T1 HRP20160577T1 (hr) 2016-07-29
HRP20160577T4 true HRP20160577T4 (hr) 2021-08-20

Family

ID=42286786

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20160577TT HRP20160577T4 (hr) 2008-12-22 2009-12-21 Liječenje osteoartritisa

Country Status (19)

Country Link
US (4) US9243061B2 (enExample)
EP (2) EP3056217B1 (enExample)
JP (3) JP5727379B2 (enExample)
KR (2) KR101898982B1 (enExample)
CN (2) CN102271705A (enExample)
AU (1) AU2009329814B2 (enExample)
BR (1) BRPI0918356B1 (enExample)
CA (1) CA2746827C (enExample)
CY (1) CY1117698T1 (enExample)
DK (1) DK2376121T4 (enExample)
ES (2) ES2886063T3 (enExample)
HK (1) HK1226938A1 (enExample)
HR (1) HRP20160577T4 (enExample)
HU (1) HUE028615T2 (enExample)
PL (1) PL2376121T5 (enExample)
RU (2) RU2011127334A (enExample)
SI (2) SI2376121T2 (enExample)
SM (1) SMT201600156B (enExample)
WO (1) WO2010071924A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010071923A1 (en) 2008-12-22 2010-07-01 The University Of Melbourne Pain treatment
AU2009329814B2 (en) 2008-12-22 2015-06-18 The University Of Melbourne Osteoarthritis treatment
CN109999195A (zh) 2012-09-20 2019-07-12 莫弗系统股份公司 类风湿关节炎的治疗
DE102013222200A1 (de) * 2013-10-31 2015-08-27 Osram Opto Semiconductors Gmbh Elektronisches Bauelement und Verfahren zum Herstellen eines elektronischen Bauelements
WO2019034985A1 (en) * 2017-08-14 2019-02-21 Zynerba Pharmaceuticals, Inc. METHODS OF TREATING ARTHROSIS USING CANNABIDIOL TRANSDERMAL GEL
WO2020104833A1 (en) * 2018-11-19 2020-05-28 4P-Pharma Composition and methods for regulating chondrocyte proliferation and increasing of cartilage matrix production
CN110075304B (zh) * 2019-05-29 2020-02-11 四川大学华西医院 一种治疗骨关节炎的药物组合物及其用途

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
PH27534A (en) 1989-07-14 1993-08-18 Schering Corp Antoganists of gm-csf derived from the carboxyl terminus
JP3267966B2 (ja) 1989-08-11 2002-03-25 アムラド・コーポレイション・リミテッド 顆粒球―マクロファージコロニー刺激因子受容体およびその誘導体における改良
US5747032A (en) 1990-08-10 1998-05-05 Amrad Corporation Limited Monoclonal antibody to human granulocyte macrophage colony stimulating factor
EP0673389A1 (en) 1992-11-19 1995-09-27 Dana Farber Cancer Institute Antibodies for gm-csf receptor and uses thereof
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
AUPP525198A0 (en) 1998-08-13 1998-09-03 Medvet Science Pty. Ltd. Monoclonal antibody inhibitor of GM-CSF, IL-3 and IL-5 and other cytokines and uses thereof
US7108852B2 (en) 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
US7455836B2 (en) * 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
JP2005507915A (ja) * 2001-10-26 2005-03-24 ノバルティス アクチエンゲゼルシャフト 変形性関節症の処置方法およびその組成物
US7381801B2 (en) 2002-02-13 2008-06-03 Ludwig Institute For Cancer Research Chimerized GM-CSF antibodies
US20040241755A1 (en) * 2003-06-02 2004-12-02 Pfizer Inc. Human cell assay to determine effect of sample compounds on Col2 enhancer expression
DE602005020743D1 (de) 2004-02-11 2010-06-02 Warner Lambert Co Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern
JP4825667B2 (ja) * 2004-03-31 2011-11-30 一和 中尾 関節炎症治療剤又は予防剤
DE602004021773D1 (de) 2004-05-05 2009-08-13 Micromet Ag Herstellung eines einkettigen fv Antikörperfragments
JP2008510168A (ja) * 2004-08-18 2008-04-03 アメリカ合衆国 骨関節炎のバイオマーカー
US20060040258A1 (en) 2004-08-23 2006-02-23 Huiyan Guo Water-soluble conjugates and methods of preparation
UA94403C2 (ru) 2005-04-18 2011-05-10 Микромет Аг Человеческое моноклональное антитело, которое нейтрализует gm-csf
SI3620171T1 (sl) * 2005-05-18 2022-09-30 Morphosys Ag Protitelesa proti GM-CSF in uporabe zanje
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
EA200801166A1 (ru) * 2005-12-01 2008-12-30 Домантис Лимитед Форматы конкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа
WO2007092939A2 (en) * 2006-02-08 2007-08-16 Morphotek, Inc. Antigenic gm-csf peptides and antibodies to gm-csf
CA2647449C (en) * 2006-03-27 2017-05-16 Medimmune Limited Binding member for gm-csf receptor
US7741273B2 (en) 2006-04-13 2010-06-22 Warsaw Orthopedic, Inc. Drug depot implant designs
EP2402013A1 (en) 2006-11-21 2012-01-04 Kalobios Pharmaceuticals, Inc. Methods of Treating Chronic Inflammatory Diseases using a GM-CSF Antagonist
WO2008080134A2 (en) * 2006-12-22 2008-07-03 Rigel Pharmaceuticals, Inc. 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors
WO2008141391A1 (en) * 2007-05-23 2008-11-27 Crc For Asthma And Airways Ltd Neutralizing antibodies
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
WO2009042854A1 (en) * 2007-09-26 2009-04-02 Musculoskeletal Research Llc Ion-channel regulator compositions and methods of using same
WO2009062238A1 (en) 2007-11-12 2009-05-22 Crc For Asthma And Airways Ltd Epitope for neutralizing antibodies
CN104072613A (zh) 2007-11-13 2014-10-01 Evec股份有限公司 与hGM-CSF结合的单克隆抗体及包含它的药物组合物
JP2011517672A (ja) 2008-03-24 2011-06-16 アボツト・バイオテクノロジー・リミテツド 骨損失を治療するための方法及び組成物
EA201001691A1 (ru) * 2008-04-28 2011-10-31 Калобайос Фармасьютикалз, Инк. Антитела к гранулоцитарно-макрофагальному колониестимулирующему фактору
WO2010071923A1 (en) 2008-12-22 2010-07-01 The University Of Melbourne Pain treatment
AU2009329814B2 (en) * 2008-12-22 2015-06-18 The University Of Melbourne Osteoarthritis treatment
SG175305A1 (en) 2009-04-23 2011-11-28 Theraclone Sciences Inc Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies

Also Published As

Publication number Publication date
WO2010071924A1 (en) 2010-07-01
JP2015143233A (ja) 2015-08-06
PL2376121T3 (pl) 2016-12-30
JP6458086B2 (ja) 2019-01-23
US9243061B2 (en) 2016-01-26
SI2376121T1 (sl) 2016-07-29
JP2012512815A (ja) 2012-06-07
CA2746827A1 (en) 2010-07-01
HRP20160577T1 (hr) 2016-07-29
AU2009329814B2 (en) 2015-06-18
BRPI0918356A2 (pt) 2020-10-06
JP5727379B2 (ja) 2015-06-03
HUE028615T2 (en) 2016-12-28
PL2376121T5 (pl) 2021-09-27
JP2017200933A (ja) 2017-11-09
HK1226938A1 (en) 2017-10-13
ES2886063T3 (es) 2021-12-16
ES2572368T5 (es) 2021-12-16
CN102271705A (zh) 2011-12-07
US20160185868A1 (en) 2016-06-30
KR20170128630A (ko) 2017-11-22
DK2376121T4 (da) 2021-08-16
BRPI0918356B1 (pt) 2022-03-08
CA2746827C (en) 2018-01-23
CY1117698T1 (el) 2017-05-17
KR101898982B1 (ko) 2018-09-14
RU2712273C2 (ru) 2020-01-28
EP3056217B1 (en) 2021-06-30
KR101799264B1 (ko) 2017-11-20
US20180066062A1 (en) 2018-03-08
CN106397591A (zh) 2017-02-15
EP2376121B1 (en) 2016-03-09
AU2009329814A1 (en) 2010-07-01
RU2011127334A (ru) 2013-01-27
SMT201600156B (it) 2016-08-31
EP2376121A1 (en) 2011-10-19
RU2016102339A3 (enExample) 2019-07-29
ES2572368T3 (es) 2016-05-31
US20200247895A1 (en) 2020-08-06
EP3056217A1 (en) 2016-08-17
EP2376121B2 (en) 2021-06-09
EP2376121A4 (en) 2013-04-03
SI2376121T2 (sl) 2021-11-30
US20120003234A1 (en) 2012-01-05
KR20110128273A (ko) 2011-11-29
RU2016102339A (ru) 2018-11-21
DK2376121T3 (en) 2016-05-30

Similar Documents

Publication Publication Date Title
HRP20160577T4 (hr) Liječenje osteoartritisa
HRP20211343T1 (hr) Protutijela protiv dkk-1
HRP20192233T1 (hr) Protutijela protiv amiloidnog beta peptida n3pglu i njihova upotreba
JP2011004758A5 (enExample)
NZ597466A (en) Recombinant anti-epidermal growth factor receptor antibody compositions
ES2721753T3 (es) Anticuerpos contra IL-6 y usos de los mismos
RU2015147300A (ru) Гуманизированные антитела к cxcr5, их производные и их применение
HRP20171992T1 (hr) Protutijela protiv cgrp
CY1120417T1 (el) Μεθοδοι για τη μειωση των επιπεδων των βασεοφιλων
NZ605980A (en) Anti-fap antibodies and methods of use
NZ702494A (en) Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
NZ610734A (en) Human antibodies to the glucagon receptor
NZ623319A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
NZ601271A (en) Cd127 binding proteins
RU2017132160A (ru) Антитела к pd-l1 и их применение для усиления функции t-клеток
JP2012511913A5 (enExample)
EA035160B9 (ru) Антитела к st2 и их применение
NZ592214A (en) Improved Interleukin-6 receptor antibody molecule
RU2013135175A (ru) Фармацевтическая композиция комплекса антитела против дигоксигенина и дигоксигенина, конъюгированного с пептидом
WO2011103567A3 (en) Peptides and methods for inducing cell death
CN104245736A (zh) 抗人死亡受体5胞外区的人源化单克隆抗体
WO2012018767A3 (en) Antibodies directed against il-17
EA201600088A1 (ru) Парентеральное введение тапентадола
JP2012025752A5 (enExample)
CY1119185T1 (el) Θεραπευτικη χρηση ειδικου προσδετη σε σχετικες me msrv ασθενειες